The competitive landscape in the global addiction treatment market is characterized by a mix of fragmentation and consolidation. While some segments of the market are dominated by a few key players offering comprehensive treatment solutions and services, others exhibit a fragmented structure with numerous small and medium-sized providers catering to specific niches or geographical regions. Major players in the market often engage in strategic partnerships, mergers, and acquisitions to enhance their market presence and expand their service offerings. Additionally, technological advancements and innovations in treatment modalities further contribute to the competitive dynamics of the market, with both established companies and new entrants vying for market share and differentiation. 'Alkermes plc (Ireland) ', 'Dr. Reddy’s Laboratories Ltd. (India) ', 'Hikma Pharmaceuticals plc (UK) ', 'Indivior PLC (UK) ', 'Mallinckrodt Pharmaceuticals (Ireland) ', 'Orexo AB (Sweden) ', 'Pear Therapeutics (US) Inc. (US) ', 'Pfizer Inc. (US) ', 'Viatris Inc. (US) ', 'American Addiction Centers, Inc. (US) ', 'Quest Diagnostics, Inc. (US) ', 'Sage Therapeutics, Inc. (US) ', 'Gilead Sciences, Inc. (US) ', 'Acadia Pharmaceuticals Inc. (US) ', 'Medications for Addiction Treatment (MAT) (US) ', 'Intra-Cellular Therapies, Inc. (US) ', 'Emergent BioSolutions Inc. (US) ', 'Hims & Hers Health, Inc. (US) ', 'Lundbeck A/S (Denmark) ', 'Cambrex Corporation (US) ', 'Caron Treatment Centers (US) ', 'Smart Recovery (US) ', 'Recovery Brands (US)', 'On February 2024, Daewoong's GERD drug Fexuclue is set to reach 24 countries within 18 months. It has already entered two countries: Korea and the Philippines. Approval has been granted in three Latin American countries: Mexico, Ecuador, and Chile, and launches are planned for this year. Additionally, Fexuclue has applied for marketing authorization in 13 countries, including China and Saudi Arabia.', 'In January 2024, KBI Biopharma, Inc. (KBI), a company within JSR Life Sciences, and Argonaut Manufacturing Services, Inc. (Argonaut), announced a strategic alliance. This partnership aims to provide biopharmaceutical clients with comprehensive manufacturing solutions for both drug substance and drug product. KBI specializes in drug development and biologics manufacturing, while Argonaut is known for its expertise in sterile fill-finish. By combining their strengths, the alliance aims to support customers in delivering clinical and commercial therapies to patients efficiently and safely.', 'In August 2023, SK Bioscience, a South Korean vaccine and biotech company, has announced a significant investment in Novavax, a global leader in protein vaccines. Through a private placement, SK Bioscience purchased 6.5 million shares of Novavax's common stock. This investment represents a shift from their previous partnership during the pandemic to a long-term collaboration focused on adapting to changes in global health. The goal is to accelerate vaccine research and expand globally, reflecting a commitment to addressing evolving health challenges beyond the pandemic.', 'In December 2023, Kindeva Drug Delivery, a global organization specializing in the development and manufacturing of drug-device combination products, and Orbia Advance Corporation's Fluorinated Solutions business (Koura®), a leader in fluoroproducts and technologies, have announced a collaborative effort. This collaboration aims to convert existing pressurized Metered Dose Inhaler (pMDI) products to Koura's environmentally friendly medical propellant, HFA 152a, also known as Zephex® 152a.'